Wuhan Institute of virology is rushing to register US patent in research? Expert: unlikely to succeed

category:Hot
 Wuhan Institute of virology is rushing to register US patent in research? Expert: unlikely to succeed


It is mentioned that the Institute and the National Center of emergency prevention and control drug engineering and technology of the Academy of military medicine of the Academy of military sciences have carried out joint research and found that remdesivir and chloroquine phosphate can effectively inhibit the infection of 2019 ncov at the cellular level, and their effect on human body remains to be clinically verified.

According to the joint statement of the above cooperation parties, for ridacivir, a drug that has not yet been listed in China and has intellectual property barriers, we applied for a Chinese invention patent (anti-2019 new coronavirus use) on January 21 in accordance with international practice and from the perspective of protecting national interests.

It is understood that ridacivir is an anti Ebola virus drug still under development by Gilead company, an American pharmaceutical company, for the treatment of Ebola haemorrhagic fever. At present, phase II and phase III clinical studies are under way.

Prior to this, Dr. merdad parsey, global chief medical officer of Geely technology, issued a statement on behalf of the company, saying that ridsivay has not been approved for listing in any country, and its safety and effectiveness have not been confirmed. In this outbreak, radcivir, as an experimental drug, was used for the emergency treatment of a small number of patients with new coronavirus infection. Gilead is working with Chinas health authorities to conduct a randomized, controlled trial to determine whether it is safe and effective to treat patients with new coronavirus infection with readcivir.

The patent applied by Wuhan virus is the new use of ridcivir against 2019 new coronavirus. Ding Sheng, director of the global health drug research and development center and Dean of the school of pharmacy of Tsinghua University, believes that Wuhan Institute of virology is unlikely to succeed.

He explained that Gilead has applied for a patent for the use of ridcivir in the treatment of coronavirus. Although the new coronavirus as a new emerging virus has not been clearly written, it has been included in the concept of coronavirus.

At the same time, according to the patent law of our country, the invention and utility model that are granted the patent right shall be novel, creative and practical. The new application for anti coronavirus of Wuhan virus is close to the application for anti coronavirus of Gilead company, and it is impossible to apply successfully.

Whats more, Gilead owns the compound structure patent of ridcivir, which is also the core patent of a drug. Ding Sheng pointed out that even if the application of Wuhan virus was successful, it could not be applied without the structural patent of Ridgeway. Its like digging the ground with a shovel. How can you dig without a shovel?

In his view, researchers think that they have new discoveries to apply for patents, which is not wrong in itself, but whether they can get patent authorization is another problem. At this time, in the context of scientific research and clinical team cooperation between China and the United States, it is not appropriate to put forward other demands.

Recently, the Wuhan Institute of virology / biosafety research center of Chinese Academy of Sciences and the National Center of emergency prevention and control drug engineering and technology of Military Medical Research Institute of Chinese Academy of military sciences have carried out joint research, making important progress in inhibiting drug screening of 2019 new coronavirus (2019 ncov).